Immunocore Holdings PLC ADR IMCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
-
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
-
Immunocore to present at upcoming investor conferences
-
Immunocore reports second quarter financial results and provides a business update
-
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Trading Information
- Previous Close Price
- $29.48
- Day Range
- $28.62–30.17
- 52-Week Range
- $27.50–40.71
- Bid/Ask
- $27.70 / $46.13
- Shares Outstanding
- 51.50M
- Market Cap
- $1.51B
- Volume/Avg
- 924,940 / 437,163
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 524
- Website
- https://www.immunocore.com
Valuation
|
Metric
|
IMCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.41 |
Price/Sales | 3.34 |
Price/Cash Flow | 90.20 |
Price/Earnings
IMCR
Financial Strength
|
Metric
|
IMCR
|
|---|---|
Quick Ratio | 4.15 |
Current Ratio | 4.47 |
Interest Coverage | −0.46 |
Quick Ratio
IMCR
Profitability
|
Metric
|
IMCR
|
|---|---|
Return on Assets (Normalized) | −0.90% |
Return on Equity (Normalized) | −2.48% |
Return on Invested Capital (Normalized) | −1.44% |
Return on Assets
IMCR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Mj#@x^! | LOCK|<FK> | $127B | |||
| Moderna Inc
MRNA
| LOCK|ny>x@%$ | LOCK|&F | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|X@^Zhw | LOCK|jm!J | $81B | |||
| argenx SE ADR
ARGX
| LOCK|d@x?&& | LOCK|YF! | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<k^ymJ# | LOCK|@W! | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cRgdTt@ | LOCK|rYlp | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%Dbh!gs | LOCK|@xF@ | $27B | |||
| Incyte Corp
INCY
| LOCK|&FP&HK | LOCK|Mf | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|h%G?sm | LOCK|rK | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|v?V%?#K | LOCK|?# | $14B |
United States